MLN4924: Unveiling Metabolic Vulnerabilities in Cancer via Neddylation Inhibition

Introduction

The landscape of cancer biology research has been transformed by the emergence of targeted small-molecule inhibitors that disrupt essential post-translational modifications. Among these, MLN4924 (also known as pevonedistat, SKU: B1036) stands out as a highly selective NEDD8-activating enzyme (NAE) inhibitor. Its unique mechanism—blocking the neddylation pathway—has unlocked new investigative avenues, especially regarding the interplay between protein homeostasis and metabolic reprogramming in cancer cells. While previous articles have primarily focused on MLN4924’s roles in host-pathogen interactions (see host-pathogen review) or its efficacy in xenograft models and cullin-RING ligase (CRL) biology (see CRL-focused review), this article delves deeper into MLN4924’s impact on cancer cell metabolism—particularly glutamine uptake and the CRL3-SPOP-ASCT2 axis—while positioning it as a pivotal tool for uncovering metabolic vulnerabilities in solid tumor models.

Mechanism of Action of MLN4924: Precision Neddylation Pathway Inhibition

NEDD8-Activating Enzyme and the Neddylation Cascade

Neddylation is a ubiquitin-like post-translational modification that conjugates the NEDD8 peptide to substrate proteins, mainly cullins. This process is catalyzed by a three-enzyme system: the E1 NEDD8-activating enzyme (NAE), the E2 NEDD8-conjugating enzyme, and an E3 ligase. The neddylation of cullins is essential for activating cullin-RING ligases (CRLs), which in turn mediate ubiquitination and subsequent proteasomal degradation of a multitude of regulatory proteins, including those controlling cell cycle progression and DNA replication.

MLN4924: Selective NAE Inhibition and Its Molecular Consequences

MLN4924 competitively binds to the nucleotide-binding domain of NAE with an impressive IC₅₀ of 4 nM, drastically outcompeting ATP and inhibiting the initial activation of NEDD8. This blockade prevents the formation of the Ubc12–NEDD8 thioester intermediate and the subsequent conjugation of NEDD8 to cullin proteins. As such, CRL activity is suppressed, leading to the stabilization of CRL substrates such as CDT1, which in turn induces cell cycle defects and DNA re-replication stress. Importantly, MLN4924 demonstrates high selectivity for NAE over related E1 enzymes—UAE, SAE, UBA6, and ATG7—minimizing off-target effects and enabling precise dissection of the neddylation pathway in cancer biology research.

Downstream Effects: Disrupted Ubiquitin-Proteasome System and Cell Cycle Regulation

The inhibition of cullin-RING ligase-mediated ubiquitination by MLN4924 leads to the accumulation of critical cell cycle regulators and DNA replication licensing factors. For example, the stabilization of CDT1 triggers re-replication and DNA damage responses, ultimately driving cell cycle arrest and apoptosis in sensitive cancer cells. These effects are dose-dependent and have been validated in multiple cellular models, such as HCT-116 colon carcinoma cells.

MLN4924 in Solid Tumor Models: Preclinical Efficacy and Translational Potential

In vivo, MLN4924 has demonstrated robust anti-tumor activity in xenograft models of various solid tumors. Notably, subcutaneous administration at doses of 30 mg/kg and 60 mg/kg significantly inhibited tumor growth in HCT-116 colon, H522 lung, and Calu-6 lung carcinoma models, with favorable tolerability profiles and minimal systemic toxicity. These findings have propelled MLN4924 into multiple phases of clinical evaluation for solid tumor indications, positioning it as a leading selective NAE inhibitor for cancer research and anti-cancer therapeutic development.

Beyond Protein Homeostasis: Neddylation Inhibition and Metabolic Reprogramming

The Centrality of Glutamine Metabolism in Tumorigenesis

Cancer cells exhibit a pronounced dependence on glutamine—a phenomenon termed "glutamine addiction"—to fuel anabolic growth, maintain redox homeostasis, and support rapid proliferation. Glutamine serves as both a carbon and nitrogen source, entering the tricarboxylic acid (TCA) cycle as α-ketoglutarate and contributing to nucleotide, amino acid, and lipid biosynthesis. High glutamine demand is a hallmark of aggressive solid tumors and is tightly regulated at the level of membrane transporters, with ASCT2 (SLC1A5) being a key facilitator of glutamine uptake.

MLN4924 Uncovers the CRL3-SPOP-ASCT2 Regulatory Axis

Recent mechanistic insights, most notably from a seminal study in Nature Communications (Zhou et al., 2022), have revealed that neddylation inhibition by MLN4924 profoundly impacts cancer cell metabolism beyond its canonical effects on cell cycle regulators. MLN4924-induced inactivation of CRL3-SPOP E3 ligase leads to the accumulation of the glutamine transporter ASCT2, thereby increasing glutamine uptake. This effect is mediated by the loss of SPOP-dependent ubiquitylation and degradation of ASCT2. Consequently, SPOP and ASCT2 reciprocally regulate glutamine metabolism: SPOP knockdown elevates ASCT2 and promotes cell growth, while dual targeting of ASCT2 (e.g., with V-9302) synergizes with MLN4924 to enhance tumor suppression.

This discovery establishes a direct mechanistic link between neddylation pathway inhibition, CRL3-SPOP activity, and metabolic reprogramming—illuminating a critical vulnerability in cancer cells that can be harnessed for combination therapies. Importantly, this metabolic angle has not been the focus of previous MLN4924-centric reviews, which have tended to emphasize protein turnover, E2 enzyme specificity, or RHEB/mTORC1 signaling (see E2 specificity discussion). Here, we uniquely explore how MLN4924’s metabolic effects open new translational strategies for solid tumor targeting.

Comparative Analysis with Alternative Neddylation Pathway Approaches

While the neddylation pathway has long been recognized as a promising therapeutic target, alternative strategies—such as genetic ablation of NEDD8 or non-selective E1 enzyme inhibition—have suffered from toxicity, lack of specificity, and limited clinical translatability. MLN4924’s exceptional selectivity for NAE, favorable pharmacological profile, and proven efficacy in preclinical solid tumor models distinguish it as a superior probe for dissecting neddylation-dependent processes in cancer biology.

Moreover, compared to other NAE inhibitors or CRL-targeted approaches, MLN4924 uniquely facilitates the study of metabolic consequences arising from neddylation blockade. For example, unlike broad-spectrum proteasome inhibitors, which induce widespread proteome destabilization, MLN4924’s targeted mechanism enables the delineation of specific substrate pathways—such as the SPOP-ASCT2 axis—thereby providing critical insights into the metabolic-adaptive responses of tumor cells.

Advanced Applications: MLN4924 as a Tool for Metabolic Vulnerability Discovery

Targeting the Tumor Microenvironment and Nutrient Addiction

The ability of MLN4924 to increase ASCT2-mediated glutamine uptake paradoxically sensitizes cancer cells to glutamine deprivation and ASCT2 inhibition. This suggests a rationale for combining MLN4924 with inhibitors of glutamine transport or metabolism to achieve synthetic lethality in glutamine-addicted tumors. Additionally, because ASCT2 upregulation correlates with poor prognosis and is observed across a range of solid tumor types—including breast, lung, and liver cancers—MLN4924’s utility extends to diverse preclinical models and patient-derived xenografts.

Enabling Rational Drug Combinations and Precision Oncology Approaches

Building on the insights from Zhou et al. (2022), researchers can now exploit MLN4924-induced metabolic rewiring as a basis for rational combination therapies. For example, the co-administration of MLN4924 and ASCT2 inhibitors (such as V-9302) has demonstrated synergistic inhibition of tumor growth, underscoring the potential for personalized strategies targeting both protein homeostasis and metabolic dependencies.

Furthermore, MLN4924’s role in metabolic regulation is distinct from the advanced discussions of RHEB neddylation and mTORC1 signaling found in other reviews (see mTORC1 signaling analysis). While those articles highlight signaling cross-talk and translational guidance, this piece foregrounds the metabolic vulnerabilities and therapeutic windows created by selective NAE inhibition in solid tumor contexts.

Practical Considerations for MLN4924 Use in Research

• Chemical Properties: MLN4924 is a solid compound (molecular weight 443.53), highly soluble in DMSO (≥22.18 mg/mL) and ethanol (≥42.2 mg/mL), but insoluble in water. Solutions should be freshly prepared and stored at -20°C for short-term use.
• Selectivity: Demonstrates robust selectivity for NAE (IC₅₀ = 4 nM), with significantly higher IC₅₀ values against UAE, SAE, UBA6, and ATG7, ensuring minimal off-target effects.
• In Vitro and In Vivo Applications: Effective in both cellular models (e.g., HCT-116) and in vivo xenograft experiments, enabling comprehensive studies from mechanistic exploration to translational validation.
• Research Focus: Ideal for studies investigating the neddylation pathway, ubiquitin-proteasome system, cell cycle regulation, and most notably, cancer cell metabolism and anti-cancer therapeutic development.

Conclusion and Future Outlook

MLN4924 has redefined the paradigm of neddylation pathway inhibition in cancer biology research. Its unique ability to reveal the metabolic vulnerabilities of cancer cells—especially through the CRL3-SPOP-ASCT2 axis—sets it apart from both broad-spectrum proteasome inhibitors and alternative NAE inhibitors. As demonstrated by recent mechanistic studies (Zhou et al., 2022), MLN4924 not only impairs cullin-RING ligase activity and cell cycle regulation but also rewires glutamine metabolism, offering new translational strategies for solid tumor targeting.

Ongoing research is poised to leverage these insights for the rational design of combination therapies, targeting both protein degradation pathways and metabolic dependencies in aggressive tumors. By integrating metabolic profiling, CRL substrate analysis, and therapeutic response data, MLN4924 continues to serve as an indispensable tool for cancer biology research and anti-cancer therapeutic development. For researchers seeking to interrogate the intricate interplay between neddylation, ubiquitination, and tumor metabolism, MLN4924 offers unparalleled specificity and translational relevance.